down arrow

HLS Therapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA40390B1094
CAD
4.91
0.01 (0.2%)

Dec 04

TSE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
BioSyent, Inc.
Knight Therapeutics, Inc.
HLS Therapeutics, Inc.
InnoCan Pharma Corp.
Fennec Pharmaceuticals, Inc.
Ayr Wellness, Inc.
NervGen Pharma Corp.
Arch Biopartners, Inc.
Defence Therapeutics Inc
Cybin, Inc.
Mindset Pharma, Inc.
Why is HLS Therapeutics, Inc. ?
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.40 times
  • Poor long term growth as Net Sales has grown by an annual rate of 1.71% and Operating profit at 8.20% over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.40 times
  • The company has reported losses. Due to this company has reported negative ROE
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 54.86%, its profits have risen by 37.9%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is HLS Therapeutics, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
HLS Therapeutics, Inc.
39.89%
1.52
34.69%
S&P/TSX 60
19.1%
1.54
14.62%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
1.71%
EBIT Growth (5y)
8.20%
EBIT to Interest (avg)
-1.32
Debt to EBITDA (avg)
3.40
Net Debt to Equity (avg)
0.68
Sales to Capital Employed (avg)
0.36
Tax Ratio
28.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.57%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.96
EV to EBIT
-32.73
EV to EBITDA
10.20
EV to Capital Employed
1.58
EV to Sales
3.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.83%
ROE (Latest)
-21.11%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company
NET PROFIT(HY)

Higher at CAD -9.69 MM

ROCE(HY)

Highest at -20.58%

INTEREST COVERAGE RATIO(Q)

Highest at 271.49

RAW MATERIAL COST(Y)

Fallen by 0.4% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 6.31%

OPERATING PROFIT MARGIN(Q)

Highest at 33.2 %

PRE-TAX PROFIT(Q)

Highest at CAD -3.42 MM

EPS(Q)

Highest at CAD -0.12

-1What is not working for the Company
CASH AND EQV(HY)

Lowest at CAD 42.11 MM

Here's what is working for HLS Therapeutics, Inc.
Interest Coverage Ratio
Highest at 271.49
in the last five periods
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Net Profit
Higher at CAD -9.69 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CAD MM)

Net Profit
At CAD -9.69 MM has Grown at 51.35%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CAD MM)

Operating Profit Margin
Highest at 33.2 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at CAD -3.42 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CAD MM)

EPS
Highest at CAD -0.12
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (CAD)

Debtors Turnover Ratio
Highest at 6.31%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by 0.4% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for HLS Therapeutics, Inc.
Cash and Eqv
Lowest at CAD 42.11 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."